London, UK: The ABPI have also used this announcement to set out that in any new industrial strategy for UK, the opportunity must be seized for the NHS to be a real engine for innovation and growth, and be the best place globally for pharmaceutical companies to research and launch new medicines.
Dr Jacintha Sivarajah, Head of Medical Affairs at the ABPI said:
“This investment in the future of UK biomedical science is a signal that this Government understands the value of investing in innovation.
The UK is already a world leader in pioneering medical breakthroughs and the pharmaceutical industry in the UK is committed to working with policymakers to ensure that this strong tradition continues.
It is estimated that for every £1 the Department of Health invests, hospitals and universities will generate £6 from public funders of research, charities and industry partners.
Looking forward to the Government’s new industrial strategy, we must make sure that the NHS is the best place globally for companies to research and launch new medicines.
Pharmaceutical companies working alongside our health ecosystem of world class universities, scientists and clinicians can be a real engine for innovation and growth, delivering tangible benefits for patients and the UK economy.”
